AAVLife is a gene therapy company focused on developing treatments for rare diseases with great unmet medical need.

AAVLife is a gene therapy company focused on developing treatments for rare diseases with great unmet medical need.

AAVLife's lead indication is for Friedreich’s Ataxia Cardiomyopathy

The goal is to commence a clinical trial in 2015 to evaluate gene therapy for heart disease associated with Friedreich’s Ataxia. An observational study will be initiated in 2014 as a run-up to treating patients in a Phase I/II study.